Učitavanje...
(i)Data Mining for Mutation-Specific Targets in Acute Myeloid Leukemia
Three mutation-specific targeted therapies have recently been approved by the FDA for the treatment of acute myeloid leukemia (AML): midostaurin for FLT3 mutations, enasidenib for relapsed or refractory cases with IDH2 mutations, and ivosidenib for cases with an IDH1 mutation. Together, these agents...
Spremljeno u:
| Izdano u: | Leukemia |
|---|---|
| Glavni autori: | , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2019
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7250137/ https://ncbi.nlm.nih.gov/pubmed/30728456 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41375-019-0387-y |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|